Deal facts
- Buyer
- Wolfram Resources Plc
- Target
- Ellipses Pharma Limited
- Deal value
- Not disclosed
- Announced
- 16 November 2026
- Status
- Possible offer
- Sector
- Healthcare
- Country
- United Kingdom
- Consideration
- shares
Wolfram Resources Plc (LSE: WFR), a Main Market listed special purpose acquisition company, confirmed on 16 November 2026 that it was in active discussions about a potential acquisition of Ellipses Pharma Ltd. The statement responded to press speculation. Because the deal would be an initial transaction under UKLR 13.4.2R, Wolfram asked the FCA to suspend the listing of its ordinary shares from 7.30 a.m. that day, and trading on the Main Market was suspended as well.
On 18 November 2026 Wolfram announced that it had signed a non-binding Memorandum of Understanding with Ellipses covering the proposed acquisition of Ellipses' entire issued share capital. The enlarged group would be re-listed on the Main Market in the Equity Shares (Commercial Companies) category. Consideration is expected to be satisfied in new Wolfram ordinary shares, with final terms to be agreed after due diligence, and a fundraise is expected alongside the relisting.
Ellipses is a London-headquartered drug development company focused exclusively on cancer, founded in 2017 by Professor Sir Chris Evans OBE. Its portfolio includes EP0031 (lunbotinib), a selective RET inhibitor in Phase 2 for RET-altered non-small cell lung cancer and partnered with Kelun-Biotech, and EP0062 (vosilasarm), an oral selective androgen receptor modulator in Phase 2 for ER+/HER2- breast cancer. Its Scientific Advisory Group includes more than 300 oncology experts. Wolfram has appointed Berenberg as Sponsor and Financial Adviser, and AlbR Capital Limited is its corporate broker.
Technical, financial and legal due diligence began immediately, with completion of the acquisition, fundraise and relisting targeted for early 2027. The transaction will be conditional on, among other things, satisfactory technical, financial and legal due diligence, agreement of final terms and definitive documentation, FCA approval and publication of a prospectus, shareholder approval, Takeover Panel approval of a Rule 9 waiver, and admission of the enlarged share capital to the Official List and the Main Market. Wolfram expects its shares to remain suspended until completion, when the existing listing is expected to be cancelled ahead of re-admission, or until an announcement that the deal will not proceed. Because the commercial terms have not yet been agreed, Wolfram says there can be no certainty that the transaction will proceed, nor on what terms.
Deal timeline
2 updates- Possible offer
Proposed Acquisition of Ellipses Pharma Limited
Disclaimer* WOLFRAM RESOURCES PLC ("Wolfram" or the "Company") Proposed Acquisition of Ellipses Pharma Limited 18 November 2026 Further to the announcement on 16 November 2026, Wolfram Resources Plc (LSE: WFR), the Main Market listed special purpose acquisition company whose ordinary shares are traded on the Equity Shares (Shell Companies) listing category, is pleased to announce th
LSE RNS - Speculation response
Wolfram Resources confirms active discussions on potential acquisition of Ellipses Pharma; listing and trading suspended
The Company confirms that it is in an active discussion regarding the potential acquisition of Ellipses Pharma Ltd
LSE RNS
For business owners
What would selling your own business involve?
Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.
Guides are free to read. Free tools require email access; indicative results are not professional advice.
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited
Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…
- Buyer
- Circle Health Holdings Limited
- Target
- CHC Healthcare Holdings Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Drugs Made In America Acquisition II Corp. to acquire Alpha AI Biotech Group
Drugs Made in America Acquisition II Corp., a Cayman Islands special purpose acquisition company listed on Nasdaq, disclosed in a Form 8-K signed November 18, 2026 that…
- Buyer
- Drugs Made In America Acquisition II Corp.
- Target
- Alpha AI Biotech Group
- Deal value
- USD 600,000,000
- Deal type
- strategic acquisition
Aimei Health Technology Co., Ltd to acquire Hera Health Solutions Inc.
Aimei Health Technology Co., Ltd (Nasdaq: AFJK), a Cayman Islands blank check company, entered into a non-binding letter of intent on November 14, 2026 for a business co…
- Buyer
- Aimei Health Technology Co., Ltd
- Target
- Hera Health Solutions Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
MaxCyte, Inc. to acquire Akron BioProducts LLC
MaxCyte, Inc., the Nasdaq-listed cell-engineering company, has agreed to acquire Akron BioProducts LLC from affiliates of Arcline Investment Management. The Securities P…
- Buyer
- MaxCyte, Inc.
- Target
- Akron BioProducts LLC
- Deal value
- USD 151,800,000
- Deal type
- strategic acquisition
New Horizon Pharma B.V. to acquire Phatebo GmbH
ZeroStack Corp. disclosed in a Form 8-K, accepted by the SEC on 9 November 2026, that on 3 November 2026 it signed a Share Purchase and Transfer Agreement with New Horiz…
- Buyer
- New Horizon Pharma B.V.
- Target
- Phatebo GmbH
- Deal value
- EUR 2,150,000
- Deal type
- strategic acquisition
Buyer history
Wolfram Resources Plc
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive